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Abstract:
Nontypable Haemophilus influenzae (NTHi) is a Gram-negative bacterium which causes
otitis media (ear infections), pneumonia, bronchitis, and sinusitis. For many years, the P6 protein
has been a leading candidate for a protein vaccine against NTHi, because it is conserved among
NTHi strains, is believed to be surface exposed, and contains binding sites for specific
antibodies. However, recent structural analysis suggests that P6 may be inserted into the outer
membrane in two orientations. Based on the interaction with its homologues in Escherichia coli
(E. coli), we proposed that P5, a transmembrane protein in NTHi, plays a role in P6’s apparent
dual membrane orientation by either helping it to flip to the surface or by deceptively binding to
P6 antibodies. Although the structure of the transmembrane region of P5 has been solved, the
structure of the C-terminal end was not known until very recently. We attempted to use nuclear
magnetic resonance (NMR) spectroscopy to solve the structure of the C-terminal end of NTHi
P5, but the protein piece we engineered was most likely denatured or aggregated in solution.
Also, flow cytometry experiments on the knockout of a P5 homologue, OmpA, in E. coli showed
improved surface antibody binding to the P6 homologue, Pal: a contradictory result to our
proposed hypotheses. Therefore, we discontinued our work with P5. A second goal of this work
was to determine the epitope for the P6 antibody 4G4 through site directed mutagenesis,
antibody binding assays, and NMR spectroscopy. Experimental results using the P6 T42E mutant
showed no difference in antibody binding to 4G4 antibodies, suggesting that either the binding is
not dependent on that single amino acid or that a different mutation is required to alter antibody
binding.
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Introduction

Infection by Nontypable Haemophilus influenzae and the role of P6

Nontypable Haemophilus influenzae (NTHi) is a nonencapsulated, Gram-negative,
pathogenic bacterium that causes otitis media (ear infection), sinusitis, pneumonia, and other
respiratory infections. Although there are cases of H. influenza infection in adults, NTHi
infection is more common in children [1, 2, 3]. In the United States, 75% of children are
diagnosed with at least one case of otitis media before their 3rd birthday, and about half of those
will experience three or more cases [1]. Otitis media is also the most common childhood illness
for which pediatricians provide prescriptions [2, 3]. The creation of a safe and effective vaccine
against NTHi would greatly reduce the occurrence of ear infections, protect against recurring
cases, and also decrease the need for antibiotics.
A protein vaccine is one that contains a specific antigenic piece of protein(s), or whole
protein(s) from the pathogenic agent rather than live or attenuated cells. The protein acts as a
target for the immune response, but it does not have the ability to cause an infection on its own.
In order for a protein to be considered a viable vaccine candidate, it must be surface exposed, the
target of bactericidal antibodies, and preferably conserved among different pathogenic strains in
order to provide broad protection. With NTHi, it has been difficult to create a protein vaccine
because of the antigenic variability of the outer membrane proteins (OMPs) throughout the
different strains [4]. Some previously studied NTHi proteins and potential vaccine candidates
include OMPs P1, P2, P4, P5, P6, D15 and TbpA/B as well as some lipopolysaccharides (LPS)
and membrane adhesion compounds [4].
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For the past twenty years, the OMP P6 has been one of the leading vaccine candidates
against NTHi [5-7]. It is a 16 kDa lipoprotein that is highly conserved among the different strains
of NTHi, meaning that a P6 vaccine could potentially target most strains of NTHi. The P6
protein also has homologues in other bacterial species, most notably the protein in Escherichia
coli (E. coli) known as “peptidoglycan associated protein” or Pal [8-10]. The exact function of
P6 has not yet been determined, but results from experiments performed on a P6 knock-out strain
of NTHi suggest that it is important in maintaining the integrity/structure of the outer membrane
[11]. The structure of a nonlipidated (NL) version of P6 (first 20 amino acids were deleted)
bound to a peptdiglycan precursor has been solved using nuclear magnetic resonance (NMR)
spectroscopy, and is shown in Figure 1.1 [12].

Figure 1.1: The structure of nonlipidated NTHi protein P6 determined by NMR
spectroscopy. A fragment of peptidoglycan precursor is shown in red. [12]

The P6 protein contains an N-terminal lipid anchor to the phospholipid bilayer of the membrane
(not shown in Figure 1.1) as well as a region that interacts with the peptidoglycan in the
periplasmic space. In vivo, the first 19 amino acids of the P6 sequence are removed prior to
lipidation and the lipid anchor (a tripalmitoyl lipid motif) is attached the Cys residue at position
20. P6 is also known to have at least three different monoclonal antibodies that bind specifically
to it: 3B9, 4G4, and 7F3 [6, 7, 11, 13, 14]. The epitopes, or specific binding sites, to those
2

antibodies have been explored more recently [13,14]. Scientists have also demonstrated
bactericidal activity of P6 antibdies [15]. Research performed by our collaborators at Rochester
General Hospital Research Institute corroborates the hypothesis that P6 is a good vaccine
candidate to protect against infection by NTHi [21, 22].

Verifying the surface exposure of P6

Although much of the results from past studies strongly support the inclusion of P6 in an
NTHi vaccine, there was still the issue of whether or not P6 was really surface exposed. For
years it was widely accepted that P6 was surface exposed based on the results of an immunogold antibody binding experiment [17, 18]. As shown in Figure 1.2, the immuno-gold
experiment is a sandwich antibody binding assay where a primary antibody binds to its target,
which must be a surface exposed protein (or molecule). The secondary antibody, which is
conjugated to a gold label, targets the primary antibody, and therefore results in a signal when
visualized by electron microscopy. However, after personal communication with the scientists
who performed these experiments, we discovered that the NTHi cells were perforated prior to the
antibody incubations. Therefore, we decided to verify the surface exposure of P6 using alternate
methods.

3

Figure 1.2: The immuno-gold electron microscopy experiment. Only surface exposed
proteins are able to bind the primary antibody and gold-labeled secondary
antibody sandwich. When researchers visualized gold particles on the surface of
NTHi cells using P6 antibodies, it was thought that P6 was indeed surface
exposed [17].

The Michel lab used a combination of flow cytometry and confocal microscopy to further
explore whether or not P6 was surface exposed [23]. Flow cytometry was used to detect
fluorescent secondary antibody in an antibody sandwich assay similar to that shown in Figure 1.2
(fluorescent tag on secondary antibody instead of gold label). Using all three P6 monoclonal
antibodies as the primary antibody, it was verified that P6 was indeed surface exposed on whole
NTHi cells [23]. The confocal microscope was then used to visualize P6 monoclonal antibodies
bound to intact NTHi cells; images demonstrated that the cells were not damaged or dead (dead
cells were stained using propidium iodide) [23]. The results of these two experiments confirm
that P6 is indeed surface exposed.
Since it is well known that P6 interacts noncovalently with peptidoglycan layer inside the
cell [12, 5, 8], and we have verified that P6 is also surface exposed, it logically follows that P6
would be a transmembrane protein. However, through the use of computational modeling, sitedirected mutagenesis, and NMR spectroscopy, the Michel lab showed that NTHi P6 was too
4

small to be a transmembrane protein [14]. To explain this contradiction, two hypotheses were
proposed: 1. There is non-P6 surface exposed protein with the same or very similar epitopes to
P6 that can interact with P6 antibodies, or 2. P6 exists in two orientations, one inside the cell and
able to bind peptidoglycan, and one outside the cell that is “flipped” through the membrane by a
mechanism that is yet to be determined.
To test the first hypothesis, the Michel lab performed simple experiments using cell
lysates [23]. Specifically, a western blot of NTHi cell lysates showed that all three P6
monoclonal antibodies (3B9, 4G4, 7F3) bind to only a single protein, and that no binding is
shown on lysates from a P6 knockout NTHi strain [23]. These results refute the first hypothesis
and indicate that the P6 monoclonal antibodies only bind to P6 and no other surface exposed
protein. In addition, the results support that P6 exists in two orientations, as mentioned in the
second hypothesis and depicted in Figure 1.3 below.

Figure 1.3: Diagram that depicts the dual orientation hypothesis for NTHi protein P6.
Here, the protein exists both in the periplasmic space, where it interacts with
peptidoglycan, and on the surface of the cell, where it can be recognized by
monoclonal antibodies. In both states the protein is tethered to the lipid bilayer by
an N-terminal lipid moiety.
5

As previously described, P6 is a member of the class of proteins known as peptidoglycanassociated lipoproteins, and is therefore expected to localize within the periplasmic space [11].
This has been supported by the fact that purification of P6 from NTHi requires strong detergents
or high temperatures [12, 35, 36]. Proteinase digestion experiments and flow cytometry
performed by the Michel lab corroborate that P6 is internally localized [15]. Incomplete
digestion of P6 in whole cells suggests that some of P6 was not accessible to Proteinase K
activity, and flow cytometric analysis showed that only a small fraction (3-4%) of whole NTHi
cells displayed detectable P6 on their surface, while a much larger percentage of cells (84.3%)
expressed detectable P6 after they were permeabilized with 0.1% Triton X-100 [15].
While these studies strongly support the dual orientation of P6 in NTHi (Figure 1.3), the
protein cannot simply diffuse through the membrane lipid bilayer. Instead, a mechanism must
exist to “flip” P6 from the periplasm to the cell surface. Such a mechanism might require a
membrane channel that recognizes P6 and transports it to the cell surface, or a “flippase” protein
that is capable of incorporating into the membrane and flipping P6 to the surface. Although this
idea of a protein that is capable of having dual orientations in a cell is a fairly novel
phenomenon, it has been described once before in the literature for the protein Lpp in
Escherichia coli (E. coli) [32].
E. coli are one of the most well studied and most utilized bacteria in science. The entire
genome of E. coli has been sequenced, and E. coli can be easily manipulated to overexpress
foreign protein using expression vectors/plasmids. Therefore, scientists often study bacterial
proteins by expressing recombinant versions of the proteins in E. coli; we can also learn a lot
about bacterial proteins by observing their homologues in E. coli. To test our hypothesis that a
“flippase” allows P6 to “flip” to the cell surface of NTHi, we turned to the homologue of P6 in
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E.coli: Pal. Pal has been well studied by numerous scientists [24-30], and has been shown to
interact with E. coli’s periplasmic protein TolB [29] and transmembrane protein OmpA [30]. The
homologue of OmpA in NTHi is P5. OmpA is a large transmembrane protein that has a Cterminal sequence similar to P6 [31]. The structure of the periplasmic C-terminal domain of
OmpA was recenty determined, and as proposed, it is highly similar to the structure of P6 [19].
The sequence of OmpA is shown in Figure 1.4a. The P6-like domain of OmpA is located in the
periplasmic space of E. coli and is known to interact with both Pal and peptidoglycan.
Interestingly, the localization and configuration of the C-terminal end of OmpA is temperature
dependent [16]. At increased temperatures (37 °C), the P6-like C-terminal end becomes
integrated into the membrane, forming a larger transmembrane porin-like structure that likely
exposes some of the P6-like sequence to the surface of the cell. This is diagramed in Figure 1.4b.
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a) APKDNTWYTGAKLGWSQYHDTGFINNNGPTHENQLGAGAFGGYQVNPYVGFE
MGYEWLGRMPYKGSVENGAYKAQGVQLTAKLGYPITDDLDIYTRLGGMVWRA
DTKSNVYGKNHDTGVSPVFAGGVEYAITPEIATRLEYQWTNNIGDAHTIGTRPD
NGMLSLGVSYRFGQGE AAPVVAPAPAPAPEVGTKHFTLKSDVLFNFNKATLK
PEGQAALDQLYSQLSNLDPKDGVVVLGYTDRIGSDAYNQGLSERRAQSVVDYLI
SKGIPADKISARGMGESNPVTGNTCDNVKQRAALIDCLAPDRRVEIEVKGLDKD
VVTTQPQA
b)

Figure 1.4: a) The amino acid sequence of E. coli OmpA with the periplasmic domain
highlighted in yellow, and b) a diagram of the irreversible temperature dependent
folding transition that occurs with the C-terminal end (yellow) of OmpA
[modified from reference 16].

This dramatic C-terminal folding transition could possibly explain how the Pal protein (or P6 in
NTHi) is flipped to the surface of the outer membrane. We proposed that Pal (P6 in NTHi)
interacts with OmpA (P5 in NTHi), which flips Pal to the surface via a “lasso-like” mechanism
using its C-terminal tail. We did also entertain the hypothesis that OmpA itself (or in the case of
NTHi, P5) mimicked Pal and interacted with Pal antibodies, thus leading us to the false
conclusion that Pal/P6 are surfaced exposed. However, protein detection experiments (described
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in reference 23) demonstrated that P6 antibodies do not interact with proteins other than P6.
Therefore, we limited our hypothesis to that in which OmpA “flips” P6 to the cell surface.
One useful technique to study proteins and protein function is the the use of a gene
knockout, where the gene that codes for the protein of interest is made inoperative (turned off),
and the protein is not expressed. We proposed that a gene knockout of P5 in NTHi could help us
determine whether or not it is involved with the flipping of P6 to the cell surface. If P5 was
responsible for flipping P6 to the cell surface, a P5 knockout would not allow P6 to be surface
exposed. However, as mentioned earlier, genetic engineering in E. coli is more easily
accomplished than in NTHi, so we utilized an OmpA knockout in E. coli (a generous gift from
Dr. Kwang Sik Kim, John Hopkins). Decreased antibody binding to surface exposed Pal in the E.
coli OmpA knockout would strongly support our hypothesis that OmpA/P5 are involved in
Pal/P6 surface exposure, necessitating further analysis.

Identifying epitopes for P6 monoclonal antibodies

The identification of specific epitopes (binding sites) for monoclonal antibodies can
provide a better understanding of the immune response to infection. In addition, epitopes for
monoclonal antibodies are often highly “immunogenic” regions and can be used as a starting
point in the design of peptides for protein vaccines. Using a protein to make a vaccine is ideal
because it eliminates the possibility of infection from the application, which could occur with a
vaccine made from an attenuated pathogen. By determining the specific antibody binding sites,
or epitope mapping, we can sometimes determine the most immunogenic regions of the protein
and therefore use those sites to design small, immunogenic peptides for vaccines.

9

Previous studies have shown, through a competitive inhibition-enzyme linked
immunosorbent assay (ELISA), that 4G4 and 7F3 compete for binding to P6 and thus share a
similar or overlapping epitope while 3B9 has an independent binding site. Mapping of the
epitope for 3B9 showed that its binding is dependent on two discontinuous regions of P6 that
come together during the folding process [13]. Studies in the Michel lab have shown, through
site-directed mutagenesis, that the binding of 7F3 is dependent on a single acidic residue at
position 40 (Asp: aspartic acid). Since the epitopes for 4G4 and 7F3 overlap, we proposed that
the epitope for 4G4 is close to Asp40, however, the exact binding site is unknown. Elucidating
the epitope for 4G4 would tell us about the antibody/antigen interaction and provide information
which could be used to create a peptide vaccine against NTHi. Peptides are easier and cheaper to
produce than full-length proteins and therefore more attractive to vaccine companies.

NMR Spectroscopy.

Nuclear magnetic resonance (NMR) spectroscopy is a technique used to analyze and
determine the structure of a wide range of compounds from small organic molecules to complex
folded proteins. The phenomenon of NMR utilizes the magnetic properties of specific atoms to
reveal chemical information [33, 34]. NMR active nuclei, including 1H, 13C, 15N, and 31P, have
an intrinsic property known as spin, and when placed in a magnetic field they absorb
electromagnetic radiation at a characteristic frequency [33, 34]. NMR spectroscopy takes
advantage of these properties by placing the sample of interest in a strong magnetic field and
pulsing with radiofrequency (RF) energy. The nuclei absorb the RF radiation, align in the
magnetic field, and give off specific and detectable energy as they relax back to equilibrium
[33,34]. The position of the peaks in the spectrum is based on the chemical shift of each NMR
10

active nuclei. Chemical shift is calculated by comparing the resonant energy of the nuclei to a
reference that is chemically unreactive (ex. tetramethylsaline) [34].
Although one dimensional NMR analysis can provide enough information to determine
the structure of a small organic molecule, protein analysis is best analyzed using two and three
dimensional techniques. Heteronuclear single quantum coherence (HSQC) is a common 2D
experiment used for protein NMR. By mapping the 1H chemical shift versus the 15N shift, the
spectrum exhibits approximately one peak for the amide group of each residue. The unique fold
of the protein results in a unique HSQC spectrum, thus resulting in its commonly used name the
“fingerprint spectrum”. Many other 2D (and 3D) experiments can then be used to “assign” the
peaks of the HSQC spectrum (ie, match each peak with its corresponding residue in the protein
sequence). Further NMR experiments, often including 3D experiments and computational
predictions, are required to determine the overall structure of a protein. After the structure of the
protein is known, the applications of NMR expand. For example, if a change in conformation is
induced upon the addition of a drug or peptide thought to interact with the protein of interest, the
specific amino acids involved in the interaction can be tracked by changes in chemical shift.
Titrating in a binding partner and tracking with NMR also allows for the calculation of binding
affinities. Overall, NMR is a highly useful and powerful technique used to analyze proteins in
solution.

In summary, we proposed to assess the role of P5 in the “flipping of P6 to the cell surface and to
identify the 4G4 binding site on P6. In the first part of our work, we set out to successfully
express and purify the P6-like C-terminal domain of P5 and to determine its structure using
NMR spectroscopy. These experiments, along with other studies in the Michel lab, would help
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us to determine the role of P5 in the surface exposure of P6. In the second part of our work, we
set out to utilize site-directed mutagenesis and sandwich ELISA analysis to identify the P6
epitope for the 4G4 antibody. If we could identify the most immunogenic regions of P6, it would
be possible to create a vaccine using only that portion of the protein, which is more cost effective
than using the whole protein and therefore highly attractive to the vaccine development industry.
Again, NMR spectroscopy would be the main tool used to validate the structure(s) of the mutant
protein.

12

2

Experimental

2.1 DNA Collection and Storage
The DNA sequence that codes for the C-terminal amino acids of interest in protein P5
were ordered from GeneArt (Invitrogen) in an ampicillin resistant DNA storage vector (puc19).
A 6-histidine repeating tag was also added to the N-terminal end of the ordered sequence. The P5
gene was subcloned into a kanamycin resistant pET28a bacterial plasmid expression vector
(Breanna Kalmeta, Michel lab). The DNA plasmid was then transformed into competent XL1Blue (Agilent) and BL-21 (Invitrogen) E. coli cells using a standard heat shock protocol. Briefly,
plasmid DNA was added to the competent cells and incubated on ice, heat shocked at 42 °C
(XL1-Blue: 45 seconds, BL-21: 30 seconds), and super optimal broth with catabolite repression
(SOC media) was added prior to a one-hour incubation at 37 °C (shaking). Cells were plated
onto luria broth (LB) containing kanamycin and incubated at 37 °C overnight.
A single colony of bacteria from each plate was then added to 25 mL of LB (10 g NaCl,
10 g tryptone, 5 g yeast extract, per 1 L) along with 25 µL of 50 mg/mL kanamycin and cultured
at 180 rpm, 37 °C overnight. Glycerol stocks were prepared for each culture (900 µL of culture +
100 µL of 80% sterile glycerol) and flash frozen in liquid nitrogen (stored at -80 °C).
The DNA was extracted and collected using a QIAprep plasmid DNA miniprep (5 mL) or
midiprep (50 mL) kit (Qiagen). The 5 or 50 mL LB cultures were prepared using 5 or 50 µL of
50 mg/mL kanamycin, respectively, and one colony from the LB plate. The cultures were
incubated (180 rpm, 37 °C) overnight. The miniprep and midiprep protocols were followed as
described by the manufacturer. DNA concentrations were calculated from OD values at 260 nm
using a UV-vis spectrophotometer.
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2.2 DNA Analysis
Subcloned and transformed DNA was detected on an agarose gel (0.5 g agarose, 50 mL
1X TAE: 4.84 g Tris, 1.14 mL glacial acetic acid, 2 mL 0.5 M EDTA, 2 µL ethidium bromide).
Samples were prepared using 10 µL of the DNA and 2 µL of loading dye. The gel was run for 30
minutes at 100 V until the tracking dye was about ¾ the way through the gel, and the DNA was
visualized and photographed under UV-light. The DNA samples were also prepared for
sequencing (2 µL T7 terminator primer, 1.5 ng DNA in water, final volume 18 µL) and sent to
the Cornell University DNA sequencing facility.

2.3 Protein Expression and Purification
The BL-21 cells containing the DNA plasmid of interest were cultured overnight (37°C)
on an LB plate containing kanamycin (50 µg/mL). A single colony from the plate was used to
inoculate a 25 mL LB overnight culture, supplemented with kanamycin (180 rpm, 37 °C). The
25 mL starter culture was added to a 1 L solution of LB with 50 µg/mL kanamycin and
incubated (140 rpm, 37 °C) until the culture absorbance at 600 nm reached about 0.6 (about 3
hours). To induce protein overexpression, 0.250 g of isopropyl β-D-1-thiogalactopyranoside
(IPTG) was added and the culture and allowed to incubate for three more hours. The cells were
harvested via centrifugation (5000xg for 15 minutes at 4 °C) and stored at -20 °C overnight.
Culture pellets were thawed at room temperature for about 30 minutes and resuspended
in 20 mL of equilibration buffer (50 mM Na2HPO4/NaH2PO4, 300 mM NaCl, pH = 7.0). The
cells were sonicated for lysis (50 W) on ice for 15 minutes (15 seconds on, 45 seconds off), and
centrifuged again at maximum speed (10,000 g) for 25 minutes at 4 °C. The pellet and an aliquot
of the solution were kept for protein analysis using gel electrophoresis.
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The 6-Histidine-tagged protein of interest was purified using a Talon bead affinity
column (Clontech) according to the manufacturer’s instructions. Approximately 3 mL of beads
were added to a column, allowed to settle, and rinsed with 10 times the bed volume with
equilibration buffer (above). The protein lysate was added to the column and allowed to rock at
room temperature for one hour or overnight at 4 °C. Column flow-through was collected, and the
column was rinsed with five times the bead volume of equilibration buffer. Elution buffer (50
mM sodium phosphate buffer, 300 mM NaCl, 150 mM imidazole, pH = 7.0) was used to elute
the protein of interest off the column. Samples were collected in 2.5 mL fractions, and protein
was detected using UV-vis absorption spectroscopy (absorbance at 280 nm). To clean the
column, five bead volumes of column cleaning buffer (20 mM MES, 0.1 M NaCl, pH = 5.0) was
run through the column followed by five bead volumes of 20% ethanol. After about 3-5 uses, the
columns were regenerated using 10 bead volumes of 0.2 M EDTA (pH = 7.0), 10 bead volumes
double distilled water, 10 bead volumes 50 mM CoCl2, seven more bead volumes of water, and
three bead volumes of 300 mM NaCl.

2.4 Protein Analysis
Eluted protein fractions were combined and concentrated in a 50 mL Amicon filter (10
kDa molecular weight cut off) centrifuge tube (5,000 g, 4 °C) to a final volume of 2.5-3.0 mL.
The protein was exchanged into a final buffer (50 mM sodium phosphate buffer, 50 mM NaCl,
pH = 7.0) using a PD-10 desalting column (GE Healthcare) according to the manufacturer’s
instructions. The final protein concentration was calculated using a BCA assay (Pierce)
performed according to the manufacturer’s instructions. Briefly, a BSA calibration curve was
prepared utilizing the absorbance of a quantified BSA stock solution and bicinchoninic acid;
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protein samples were incubated with the bicinchoninic acid whose colorimetric exposure is
dependent on the protein concentration and length of exposure (562 nm). Protein sample
concentrations were estimated using the BSA standard concentration curve.
The samples collected from the column were visualized using a 10% non-reducing SDSPAGE gel. (Separating gel: 3.27 mL 30% acrylamide/bisacrylamide, 3.33 mL Tris/sodium
dodecyl sulfate (SDS) buffer pH = 8.0, 1.28 mL distilled water, 2.12 mL 50% glycerol, 100 µL
ammonium persulfate (APS), 10 µL tetramethylenediamine (TMED), stacking gel: 405 µL 30%
acrylamide/bisacrylamide, 775 µL Tris/SDS buffer pH = 8.0, 1.95 mL distilled water, 20 µL
APS, 5 µL TMED). The gel apparatus was filled with 1X cathode buffer (6.06 g Tris, 8.96 g
Tricine, 5 g SDS, 500 mL distilled water) inside the gel holder, and 1X anode buffer ( 12.1 g
Tris, 500 mL distilled water, pH = 8.9) to the fill line in the apparatus. Samples were prepared
and loaded onto the gel as described: 4 µL protein ladder and 10-12 µL of protein solutions (10
µL of sample and 10 µL of 2X sample buffer: 25 mL 1M Tris-HCl pH 6.8, 2 g 2% SDS, 10 mL
glycerol, 0.01 g bromophenol blue). The following samples were run on the gel to assess the
purification protocol: cell pellet after lysis (resuspended in equilibration buffer), cell lysate,
column flow-through, first wash, protein sample, and final wash from the column. The gel was
run for ten minutes at 120 V and then for 45 minutes at 150-180 V. The gel was stained in
Coomassie blue (200 mg Coomassie blue, 100 mL methanol, 20 mL glacial acetic acid, 80 mL
distilled water) for one hour. The gel was then removed and rinsed in destaining solution (100
mL methanol, 20 mL glacial acetic acid, 80 mL distilled water) for one hour, and stored in
distilled water before visualization via a digital camera.
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2.5 Site Directed Mutagenesis
A QuikChange II kit (Agilent) was used to prepare the P6 T42E mutant (according to the
manufacturer’s instructions). The forward and backward primers needed for the mutation were
designed for optimal melting temperatures and ordered from IDT.
Primers:
T42E (ACT  GAA)
Primer lengths: 68 nts
Tm: 79.2 ⁰C
FWD 5'-acgttacaataccgtttatttcggttttgataaatatgacattgaaggtgaatacgttcaaatcttag-3'
BWD 5'-ctaagatttgaacgtattcaccttcaatgtcatatttatcaaaaccgaaataaacggtattgtaacgt-3'

The plasmid DNA containing wild-type P6 was collected using a miniprep kit as
previously described. The concentration of the DNA was estimated using the absorbance at 260
nm and diluted to about 5 ng/µL in water. The primers were diluted to 50 ng/µL in water. To set
up the mutagenesis reaction, 5 µL of 10X buffer reagent, 4 µL of wild type DNA, 4 µL forward
primer, 4 µL backward primer, 1 µL dNTP, and 32 µL of water were added to a small thinwalled tube. After quickly/gently centrifuging down the solution, 1 µL of Pfu Ultra DNA
polymerase was added, the tube placed in one of the thermalcycler wells, and the mutant
program was run for a total of 2 hours (95 °C for 30 seconds, 55 °C for one minute, 68 °C for 5
minutes, cycle 16 times). The sample was put on ice for about 2 minutes before 1 µL of Dpn 1
enzyme was added. After another brief spin down in the centrifuge, the sample was incubated at
37 °C in a water bath for about 1.5 hours. The Dpn-1 digested DNA was transformed into XL-1
blue cells as described above (briefly, 50 µL cells thawed on ice were pipetted into a pre-chilled
15 mL round bottom tube; 2 µL of the Dpn 1 digested DNA was added and the cells and
incubated on ice for 30 minutes; cells were heat shocked at 42 °C for 45 seconds and placed on
ice for 2 minutes; 900 µL of preheated (42 °C) SOC media broth (2 g bactotryptone, 0.5 g yeast
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extract, 0.05 g NaCl, 1 mL 250 mM KCl, -brought to 100 mL with water and autoclaved, 0.5 mL
syringe filtered 2M MgCl2, 2 mL 1 M glucose) was added to the cells which were then incubated
(250 rpm, 37 °C) for one hour). The cell culture was plated in 250 µL, 200 µL, 100 µL, and 50
µL aliquots onto separate kanamycin LB agar plates and incubated overnight at 37 °C. The
colonies that grew on the plates were used to make glycerol stocks as previously described. The
DNA was extracted from each culture as previously described and the mutation was confirmed
by DNA sequencing at Cornell University.

2.6 ELISA
A sandwich enzyme linked immunosorbant assay (ELISA) was performed using the P6
wild-type and P6 T42E mutant protein samples. Both protein samples were diluted to 1 µg/mL
and 0.5 µg/mL; 100 µL of the stock solutions were added to the wells of two rows (one row per
sample) of a 96 well plate. The plate was incubated at room temperature for two hours and then
at 4 °C overnight. The plate was washed 5 times with PBS/0.1% Tween wash buffer solution at
room temperature, and blocked with 200 µL of blocking buffer (PBS/3 % skim milk/0.1 %
tween) for one hour at 37 °C. After 5 more washes, 200 µL of a 1/10th stock of 7F3 antibody was
added to row A, and 200 µL of a 1/10th stock of 4G4 was added to row E. 100 µL of blocking
buffer were added to the remaining wells. A serial dilution was performed on the antibody (7F3:
A to B to C; 4G4 E to F to G to H, with D serving as a blank). This pattern of addition is outlined
below for a 96 well plate (Figure 2.1). The plate was incubated at room temperature for one hour
and then washed five times; 100 µL of a 1/10,000 dilution of secondary antibody (goat antimouse IgG HRP conjugate) was added to each well. The plate was incubated for one hour at
room temperature and washed again; 100 µL of the TMB substrate was added to each well. The
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plate was allowed to develop for 30 minutes in the dark, and the absorbances were recorded at
450 nm using an absorption plate reader (BioTek).

Figure 2.1: Diagram that explains what was added to each well of the 96 well plate for the
ELISA experiment. Columns were filled with either 100 ng (wild type: 1,2 T42E: 5,6) or
50 ng (wild type: 3,4 T42E: 7,8) of protein. The 7F3 antibody was diluted from rows
A-C, and 4G4 from rows E-H. Columns 9-12 were not used for this experiment.

2.7 NMR
The protein samples that were used for NMR spectroscopy were cultured in M9 minimal
media (M9 salts: 34 g Na2HPO4, 15 g KH2PO4, 2.5 g NaCl, in 1 L distilled water, autoclaved;
M9 minimal media: 200 mL M9 salts, 1 g 15NH4Cl, pH = 7.4, in 1 L distilled water – autoclaved
and supplemented with 2 mL 1 M MgSO4, 100 µL 1 M CaCl2, 5 g glucose) with 15N-labeled
ammonium chloride as its sole nitrogen source. The NMR sample was prepared with 50 µL of
D2O and 450 µL of concentrated protein sample. All of the NMR experiments were run on a
Bruker 500 MHz NMR spectrometer at 25 °C. A 1D 1H NMR spectrum was collected to confirm
the presence of folded protein peaks. A 1H-15N HSQC (hsqcetgp experiment) spectrum was also
collected; manual shimming was used as well as auto tuning and matching. The command
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“pulsecal” was used to auto calibrate the 90 degree pulse. The standard Bruker parameters were
used with the following modifications: the attenuation level was changed to 2 dB, nucleus F1
was set to 15N and the F2 channel was 1H, the nitrogen transmitter offset (nucleus O2P) was set
to 120 ppm, gradient strength changed to 8.1 G cm-1, sweep width for F2 was 13 ppm and F1
was 40 ppm, and the number of data points was 1024 and 256 with number of scans set to 8. The
Bruker software was used to process the data and overlap the spectra of the wild-type protein
with the P6 T42E mutant.
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3

Results
DNA sequencing was used to confirm that the correct coding sequence was being used

during each experiment. The DNA sequence for the nonlipidated form of NTHi protein P6 is
shown in Figure 3.1. The sequence for the P6-like C-terminal domain of NTHi protein P5,
referred to as Sep5, is shown in Figures 3.2 and 3.3. Similarly, the DNA sequence for the P6
T42E mutant is shown in Figure 3.4. For Figures 3.1, 3.3, and 3.4 the BamH1 (yellow) and Nco1
(blue) restriction enzyme sites used to insert the sequence, and the histidine tag (red) used in
protein purification are highlighted. Figure 3.2 traces the amino acid sequence coded for by the
Sep5 DNA. All together, these results show that subcloning and site-directed mutagenesis were
successful as determined by DNA sequencing analysis.
Representative DNA and protein gels are shown in Figures 3.5-3.8, including protein gels
for Sep5 and wild-type P6 and a protein and DNA gel for P6 T42E. Figure 3.5 is a Commassie
blue stained SDS PAGE gel that contains samples collected during protein purification of Sep5.
The Sep5 band (~16 kDa) is present throughout the process and is the only remaining band after
the purification step. A similar purification process was performed for P6 and the P6 T42E
mutant (P6 ~ 17 kDa, Figure 3.7). Figure 3.6 shows the Coomassie stained gel which includes
samples from the Sep5 purification as well as the concentrated purified Sep5 samples that was
used for NMR experiments (molecular weight standards omitted). The protein gels demonstrate
that the protein of interest was present in the purified samples, and was the correct size when
compared to the molecular weight standards used. The DNA gel in Figure 3.8 confirms the
presence and correct molecular weight of purified DNA samples of the P6 T42E mutant which
were sent for sequencing. A BCA assay standard curve was used to estimate the protein
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concentration of the NMR protein samples, as shown in Figure 3.9. The BCA assay allowed us
to determine the protein sample concentrations for our NMR experiments (about 1 mg/mL).
Figure 3.10 is the 1D proton NMR spectrum of the Sep5 sample. The NMR spectra did
not show peaks to indicate the presence of folded protein (only water peak at 4.7 ppm). Figure
3.11 shows the results of the flow cytometry experiment (Joy Snyder- Michel lab) performed on
the E. coli OmpA knockout. Flow cytometry demonstrated that anti-Pal antibody does bind to the
surface of the OmpA knockout cells (the anti-Pal surface stained cells are contained within the
square inset and the percentage of stained cells is located above the inset).
The proton NMR spectrum of the P6 T42E mutant is shown in Figure 3.12, and the
presence of multiple peaks indicates folded protein. The overlapped HSQC NMR spectra of
wild-type P6 and T42E mutant is shown in Figure 3.13 with no observable differences in
chemical shifts for the peaks of the wild type (blue) or T42E mutant (red). The peaks in the
HSQC spectra are spread out which confirms folded protein. This shows that the amino acids are
interacting with a specific environment and are not all exposed to the solvent as in an unfolded
protein, which would cause the peaks to be clustered and overlapping. The sandwich ELISA
results for the P6 T42E mutant at 100 and 50 ng per well using 7F3 and 4G4 antibodies are
shown in Figure 3.14 and 3.15. Both demonstrate a similar binding affinity of the proteins to
both antibodies. The last two figures show DNA sequences for the P6 T42E mutant and the
corresponding DNA chromatogram (Figure 3.16) and the DNA sequence of the P6 T42E mutant,
which was verified after the ELISA and NMR data were collected (Figure 3.17). We repeated
DNA sequencing on our samples to verify the presence of the mutation after collecting our data
which showed remarkably similar properties between wild-type and mutant proteins.
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Actual NL P6 DNA sequence (reverse complement):
GGATCCTACTAGTACGCTAACACTGCACGACGGTTTTTAGAATATGCAGCTTCATCA
TGACCTAATACTGCAGGTTTTTCTTCACCGTAAGATACTGTGCCTAATTTACCAGCAT
CAACACCTTTACCAGCTAAATAACCTTTAACTGCATCTGCACGACGTTGGCCTAATG
CGATGTTGTATTCTGGTGTACCACGTTCATCAGTGTTACCTTCTACTAATACTTTAGC
AGCTGGCGTTGCATTTAAATATGCAGCGTGCGCGTCTAAGATTTGAACGTATTCACC
AGTAATGTCATATTTATCAAAACCGAAATAAACGGTATTGTAACGTTGTTGAAGATC
AGCAACAGAGTAACCGCCAAAAGTTTGAGCAGCACCATTGCCTGCAGCATCGTTGTT
AGATGAACTCATATGGCTGCCGCGCGGCACCAGGCCGCTGCTGTGATGATGATGAT
GATGGCTGCTGCCCATGG
DNA sequencing results for WT NL P6 6/19/11 (reverse complement):
GGATCCTACTAGTACGCTAACACTGCACGACGGTTTTTAGAATATGCAGCTTCATCA
TGACCTAATACTGCAGGTTTTTCTTCACCGTAAGATACTGTGCCTAATTTACCAGCAT
CAACACCTTTACCAGCTAAATAACCTTTAACTGCATCTGCACGACGTTGGCCTAATG
CGATGTTGTATTCTGGTGTACCACGTTCATCAGTGTTACCTTCTACTAATACTTTAGC
AGCTGGCGTTGCATTTAAATATGCAGCGTGCGCGTCTAAGATTTGAACGTATTCACC
AGTAATGTCATATTTATCAAAACCGAAATAAACGGTATTGTAACGTTGTTGAAGATC
AGCAACAGAGTAACCGCCAAAAGTTTGAGCAGCACCATTGCCTGCAGCATCGTTGTT
AGATGAACTCATATGGCTGCCGCGCGGCACCAGGCCGCTGCTGTGATGATGATGAT
GATGGCTGCTGCCCATGG
Figure 3.1: The reverse complement DNA sequence for nonlipidated P6 wild-type
(top), and results from sequencing after subcloning ordered DNA into a pET28a
vector and transforming into competent E.coli XL-1 blue cells (bottom).
Highlighted are the BamH1 (yellow) and Nco1 (blue) restriction enzyme sites.
The sequences are identical. Start and Stop codons are underlined.
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Gene name: NTHi_P5_C-term 1/10/2011 Geneart No:1100961
Gene length: 488 bp
SacI NcoI
GAGCTCCCATGGGTAGCAGCCATCATCATCACCATCATAGCAGCGGTCTGGTTCCGCGTG
1--------+---------+---------+---------+---------+---------+
CTCGAGGGTACCCATCGTCGGTAGTAGTAGTGGTAGTATCGTCGCCAGACCAAGGCGCAC
M__G__S__S__H__H__H__H__H__H__S__S__G__L__V__P__R__G
1
3
5
7
9
11
13
15
17
NdeI
GTAGCCATATGTTTGGTGGTTATCAGATTCTGAATCAGGATAATCTGTATGAAGATGCCA
61-------+---------+---------+---------+---------+---------+
CATCGGTATACAAACCACCAATAGTCTAAGACTTAGTCCTATTAGACATACTTCTACGGT
__S__H__M__F__G__G__Y__Q__I__L__N__Q__D__N__L__Y__E__D__A__N
19
21
23
25
27
29
31
33
35
37
ATGATGTGACCTTTGCATTTGGTAAAGCCAATCTGAAACCGCAGGCACAGGCAACCCTGG
121------+---------+---------+---------+---------+---------+
TACTACACTGGAAACGTAAACCATTTCGGTTAGACTTTGGCGTCCGTGTCCGTTGGGACC
__D__V__T__F__A__F__G__K__A__N__L__K__P__Q__A__Q__A__T__L__D
39
41
43
45
47
49
51
53
55
57
BspMI
ATAGCATTTATGGTGAAATGAGCCAGGTTAAAAGCGCAAAAGTTGCAGTTGCAGGTTATA
181------+---------+---------+---------+---------+---------+
TATCGTAAATACCACTTTACTCGGTCCAATTTTCGCGTTTTCAACGTCAACGTCCAATAT
__S__I__Y__G__E__M__S__Q__V__K__S__A__K__V__A__V__A__G__Y__T
59
61
63
65
67
69
71
73
75
77
PvuI
CCGATCGTATTGGTAGTGATGCCTTTAATGTTAAACTGAGCCAGGAACGTGCAGATAGCG
241------+---------+---------+---------+---------+---------+
GGCTAGCATAACCATCACTACGGAAATTACAATTTGACTCGGTCCTTGCACGTCTATCGC
__D__R__I__G__S__D__A__F__N__V__K__L__S__Q__E__R__A__D__S__V
79
81
83
85
87
89
91
93
95
97
AgeI
TTGCCAATTATTTTGTTGCAAAAGGTGTTGCAGCCGATGCAATTAGCGCAACCGGTTATG
301------+---------+---------+---------+---------+---------+
AACGGTTAATAAAACAACGTTTTCCACAACGTCGGCTACGTTAATCGCGTTGGCCAATAC
__A__N__Y__F__V__A__K__G__V__A__A__D__A__I__S__A__T__G__Y__G
99
101
103
105
107
109
111
113
115
117
BstEII/AgeI
BclI
GTAAAGCAAATCCGGTTACCGGTGCAACCTGTGATCAGGTTAAAGGTCGTAAAGCACTGA
361------+---------+---------+---------+---------+---------+
CATTTCGTTTAGGCCAATGGCCACGTTGGACACTAGTCCAATTTCCAGCATTTCGTGACT
__K__A__N__P__V__T__G__A__T__C__D__Q__V__K__G__R__K__A__L__I
119
121
123
125
127
129
131
133
135
137
BamHI
TTGCATGTCTGGCACCGGATCGTCGTGTTGAAATTGCAGTTAATGGCACCAAATAAGGAT
421------+---------+---------+---------+---------+---------+
AACGTACAGACCGTGGCCTAGCAGCACAACTTTAACGTCAATTACCGTGGTTTATTCCTA
__A__C__L__A__P__D__R__R__V__E__I__A__V__N__G__T__K__*__
139
141
143
145
147
149
151
153
155

Figure 3.2: The DNA (black) and amino acid (blue) sequence for the P6-like C-terminal end of
P5, as ordered through Geneart (optimized for E.coli expression). Also shown, above the
DNA sequence and in italics, are the DNA restriction enzyme sites that exist in the code.
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Sep5 actual sequence (reverse complement):
GGATCCTTATTTGGTGCCATTAACTGCAATTTCAACACGACGATCCGGTGCCAGACA
TGCAATCAGTGCTTTACGACCTTTAACCTGATCACAGGTTGCACCGGTAACCGGATT
TGCTTTACCATAACCGGTTGCGCTAATTGCATCGGCTGCAACACCTTTTGCAACAAA
ATAATTGGCAACGCTATCTGCACGTTCCTGGCTCAGTTTAACATTAAAGGCATCACT
ACCAATACGATCGGTATAACCTGCAACTGCAACTTTTGCGCTTTTAACCTGGCTCATT
TCACCATAAATGCTATCCAGGGTTGCCTGTGCCTGCGGTTTCAGATTGGCTTTACCA
AATGCAAAGGTCACATCCATATGGCTACCACGCGGAACCAGACCGCTGCTATGATG
GTGATGATGATGGCTGCTACCCATGG
DNA sequence result 6/22/11- B SEP5 #1 (reverse complement):
GGATCCTTATTTGGTGCCATTAACTGCAATTTCAACACGACGATCCGGTGCCAGACA
TGCAATCAGTGCTTTACGACCTTTAACCTGATCACAGGTTGCACCGGTAACCGGATT
TGCTTTACCATAACCGGTTGCGCTAATTGCATCGGCTGCAACACCTTTTGCAACAAA
ATAATTGGCAACGCTATCTGCACGTTCCTGGCTCAGTTTAACATTAAAGGCATCACT
ACCAATACGATCGGTATAACCTGCAACTGCAACTTTTGCGCTTTTAACCTGGCTCATT
TCACCATAAATGCTATCCAGGGTTGCCTGTGCCTGCGGTTTCAGATTGGCTTTACCA
AATGCAAAGGTCACATCCATATGGCTACCACGCGGAACCAGACCGCTGCTATGATG
GTGATGATGATGGCTGCTACCCATGG
Figure 3.3: The reverse complement DNA sequence for the P6-like C-terminal domain
of P5, known as Sep5 (top), and results from sequencing after subcloning the
DNA into the pET28a vector (bottom). Highlighted are the His tag (red), and
BamH1 (yellow) and Nco1 (blue) restriction enzyme sites. Start and stop codons
are underlined. The sequences are identical.
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Actual NL P6 sequence (reverse complement):
GGATCCTACTAGTACGCTAACACTGCACGACGGTTTTTAGAATATGCAGCTTCATCA
TGACCTAATACTGCAGGTTTTTCTTCACCGTAAGATACTGTGCCTAATTTACCAGCAT
CAACACCTTTACCAGCTAAATAACCTTTAACTGCATCTGCACGACGTTGGCCTAATG
CGATGTTGTATTCTGGTGTACCACGTTCATCAGTGTTACCTTCTACTAATACTTTAGC
AGCTGGCGTTGCATTTAAATATGCAGCGTGCGCGTCTAAGATTTGAACGTATTCACC
AGTAATGTCATATTTATCAAAACCGAAATAAACGGTATTGTAACGTTGTTGAAGATC
AGCAACAGAGTAACCGCCAAAAGTTTGAGCAGCACCATTGCCTGCAGCATCGTTGTT
AGATGAACTCATATGGCTGCCGCGCGGCACCAGGCCGCTGCTGTGATGATGATGAT
GATGGCTGCTGCCCATGG
P6 T42E Sequence A1: 1/18/12:
GGATCCTACTAGTACGCTAACACTGCACGACGGTTTTTAGAATATGCAGCTTCATCA
TGACCTAATACTGCAGGTTTTTCTTCACCGTAAGATACTGTGCCTAATTTACCAGCAT
CAACACCTTTACCAGCTAAATAACCTTTAACTGCATCTGCACGACGTTGGCCTAATG
CGATGTTGTATTCTGGTGTACCACGTTCATCAGTGTTACCTTCTACTAATACTTTAGC
AGCTGGCGTTGCATTTAAATATGCAGCGTGCGCGTCTAAGATTTGAACGTATTCACC
TTCAATGTCATATTTATCAAAACCGAAATAAACGGTATTGTAACGTTGTTGAAGATC
AGCAACAGAGTAACCGCCAAAAGTTTGAGCAGCACCATTGCCTGCAGCATCGTTGTT
AGATGAACTCATATGGCTGCCGCGCGGCACCAGGCCGCTGCTGTGATGATGATGAT
GATGGCTGCTGCCCATGG
Figure 3.4: The reverse complement DNA sequence for the actual nonlipidated P6 (top),
and results from sequencing of the T42E site-directed mutant, post QuikChange
kit (bottom). Highlighted are the codes for threonine (gray) and glutamic acid
(green) both at amino acid position 42 in the chain, the BamH1 (yellow) and
Nco1 (blue) restriction enzyme sites, and the His tag (red). Start and stop codons
are underlined.
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Figure 3.5: Protein gel with results from purification of two Sep5 E. coli BL-21 pellets.
Lanes are from left to right: protein ladder (L), Sep5 BL-21 pellet after lysis and
centrifugation (1), lysed solution added to column (2), column runoff (3), eluted Sep5
protein sample (4); samples repeated in the last four lanes using a second pellet (5-8).
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Figure 3.6: Image of a protein gel with lanes loaded from left to right: solution from
Sep5 BL-21 after lysed and centrifuged (1), column runoff (2), eluted Sep5
protein sample (3), a second lysed and centrifuged Sep5 BL-21 pellet (4), solution
from lysed and centrifuged pellet (5), column runoff (6), eluted Sep5 protein
sample (7), and the Sep5 NMR sample (8).
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Figure 3.7: Images of protein gels with results from purification for, NL P6 BL-21 pellet (top)
lanes are, from left to right: protein ladder (L), NL P6 BL-21 lysed solution added to
column (1), column runoff (2), column rinse (3) (no visible bands), and eluted NL P6
protein samples 1-5 (4-8 respectively). And P6 T42E BL-21 pellets (bottom) , loaded
from left to right: protein ladder (L), P6 T42E lysed solution added to column (1),
column rinse (2), P6 T42E protein samples 1-3 (3-5 respectively), a second P6 T42E
lysed solution (6), column rinse (7), and two T42E protein elution samples (8 and 9).
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Figure 3.8: Image of a DNA gel loaded from left to right with DNA ladder (L), and
miniprepped DNA samples from 6 growths of NL P6 T42E XL-1 blue E. coli
cells. (plate A1-4 and plate B1-2 respectively). These samples were later sent for
sequencing to confirm if mutation worked. The DNA ladder was too faint to
accurately label.
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Figure 3.9: Example of a standard curve (absorbance vs concentration) that was
calculated using bovine serum albumin and used to better estimate the
concentration of protein in our NMR samples. In this example the NL P6
protein sample had an absorbance of 1.153, which corresponds to a
concentration of 1048 µg/mL.
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Figure 3.10: The 1H NMR spectrum taken of the sample containing protein Sep5 in D2O

\
Figure 3.11: Flow cytometry experiment results (performed by Joy Snyder of the
Michel lab) of WT strain and OmpA knockout of E. coli. Two different antibodies
that bind to Pal were tested: California antibody (gift from Dr. Judith Hellman –
UC San Francisco) and France antibody (gift from Dr. Roland Lloubes – CNRSAix-Marseille University, France).
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Figure 3.12: 1H NMR spectrum of P6 T42E protein sample in D2O
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a)

b)
Figure 3.13: a) Full scan and b) zoomed in shot of the overlapping HSQC NMR
spectrum of WT P6 protein (blue/ light blue) and P6 T42E mutant protein
(red/ pink).
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P6 ELISA: 100 ng protein/well, 7F3 antibody
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Figure 3.14: The sandwich ELISA results for 7F3 antibody binding to the P6
T42E mutant at 100 (top) and 50 (bottom) ng/well.
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P6 ELISA: 100 ng protein/well , 4G4 antibody
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Figure 3.15: The sandwich ELISA results for 4G4 antibody binding to the P6
T42E mutant at 100 (top) and 50 (bottom) ng/well.
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Figure 3.16: A chromatogram of the DNA sequencing results for the P6 T42E mutant.
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Actual NL P6 sequence (reverse complement):
GGATCCTACTAGTACGCTAACACTGCACGACGGTTTTTAGAATATGCAGCTTCATCA
TGACCTAATACTGCAGGTTTTTCTTCACCGTAAGATACTGTGCCTAATTTACCAGCAT
CAACACCTTTACCAGCTAAATAACCTTTAACTGCATCTGCACGACGTTGGCCTAATG
CGATGTTGTATTCTGGTGTACCACGTTCATCAGTGTTACCTTCTACTAATACTTTAGC
AGCTGGCGTTGCATTTAAATATGCAGCGTGCGCGTCTAAGATTTGAACGTATTCACC
AGTAATGTCATATTTATCAAAACCGAAATAAACGGTATTGTAACGTTGTTGAAGATC
AGCAACAGAGTAACCGCCAAAAGTTTGAGCAGCACCATTGCCTGCAGCATCGTTGTT
AGATGAACTCATATGGCTGCCGCGCGGCACCAGGCCGCTGCTGTGATGATGATGAT
GATGGCTGCTGCCCATGG
P6 T42E Mutant: 5/23/12:
GGATCCTACTAGTACGCTAACACTGCACGACGGTTTTTAGAATATGCAGCTTCATCA
TGACCTAATACTGCAGGTTTTTCTTCACCGTAAGATACTGTGCCTAATTTACCAGCAT
CAACACCTTTACCAGCTAAATAACCTTTAACTGCATCTGCACGACGTTGGCCTAATG
CGATGTTGTATTCTGGTGTACCACGTTCATCAGTGTTACCTTCTACTAATACTTTAGC
AGCTGGCGTTGCATTTAAATATGCAGCGTGCGCGTCTAAGATTTGAACGTATTCACC
TTCAATGTCATATTTATCAAAACCGAAATAAACGGTATTGTAACGTTGTTGAAGATC
AGCAACAGAGTAACCGCCAAAAGTTTGAGCAGCACCATTGCCTGCAGCATCGTTGTT
AGATGAACTCATATGGCTGCCGCGCGGCACCAGGCCGCTGCTGTGATGATGATGAT
GATGGCTGCTGCCCATGG
Figure 3.17: The reverse complement DNA sequence for the actual nonlipidated P6
(top), and results from a second sequencing of the P6 T42E mutant DNA after
ELISA and NMR experiments were performed (bottom). Highlighted are the code
for threonine (gray) and glutamic acid (green) both at amino acid position 42 in
the chain, the BamH1 (yellow) and Nco1 (blue) restriction enzyme sites, and the
His tag (red). Start and stop codons are underlined.
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4

Discussion

4.1 Subcloning and mutagenesis
The truncated nonlipidated P6 was created by removing the first 19 amino acid residues
from the N-terminal end of NTHi P6. Those residues make up the signal sequence which calls
for the posttranslational addition of a lipid moiety that tethers the protein to the cell membrane;
without the signal sequence the protein is more soluble and is folded (as seen by NMR), and
hence easier to express and purify. Previous members of the Michel lab worked with the
lipidated version of P6 (maintaining the first 19 amino acids), but the protein aggregated and/or
unfolded readily (as seen with NMR spectroscopy). Therefore, all wild-type and mutant P6
proteins described in this thesis were nonlipidated.
The gene containing the C-terminal P6-like domain of P5 (named “Sep5”) was
synthesized by the GeneArt Company (Invitrogen) and placed into a puc19 vector (Figure 3.2).
Once received, the Michel lab subcloned the Sep5 gene into pET28a vector containing a LacZ
overexpression promoter region. The P6 sequence aligns relatively closely to the OmpA
sequence with 27.4% identical and 58.2% similar amino acids, and most of the homology
occurring at the C-terminal end of OmpA (Figure 4.1). Also, a recent structure of the C-terminal
end of OmpA (P5 homolog in E. coli) confirms that the structure is similar to that of P6. A
comparison of the structures of NTHi P6 and the C-terminal end of an OmpA protein are
illustrated in Figure 4.2. This figure demonstrates the structural similarities between the two
proteins.
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Figure 4.1: The BLAST protein sequence alignment of NTHi P6 (P10324) and E.coli
OmpA (P0A910). Matching amino acid residues are marked with an asterisk and
similar amino acids with dots. The sequences are 27.4% identical (42/153) and
58.2% similar (89/153). Most of the homology is located at the C-terminal end of
OmpA.

Figure 4.2: Protein structures of NTHi P6 (PDB ID: 2AIZ), left, and C-terminal tail of
OmpA from Acinetobacter Baumannii (PDB ID: 3TD4), right. Alpha helices are
colored red and Beta sheets in yellow.
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Confirming correct DNA sequences was an important part of each phase of this project.
All genes encoding for our proteins of interest were subcloned into pET28a vectors, which were
transformed into both E. coli XL-1blue cells (for DNA storage) and BL-21 cells (for protein
expression). There were three different proteins used throughout the course of this study. The
wild-type nonlipidated P6 was used, since the lipidated version of P6 did not fold properly and
was not easily purified, as determined through NMR analysis [14]. The sequencing results for
Sep5 confirmed that the designed C-terminal end of P5 did subclone correctly into the pET28a
vector (Figure 3.3). Also, after several failed attempts, site-directed mutagenesis was successful,
resulting in creation of the P6 T42E mutant (Figure 3.4). Mutagenesis was re-confirmed prior to
experimentation on P6 T42E (Figure 3.16 and 3.17).
DNA sequencing results received from the Cornell Life Science Core Laboratories
Center included a DNA chromatogram (Figure 3.16) of the DNA bases on the reverse strand of
DNA. Occasionally the program could not decipher which base was present at a specific location
and would simply enter an “N” in the sequence. Although it was tedious, all of the “N”s were
found in the chromatogram to determine if there was a mistake in the sequencing or in the DNA
itself. There were occasional point mutations, but all were contained within the “wobble” base,
so the correct amino acid sequence was maintained.
The first few attempts at creating the P6 T42E mutant were not successful. After further
analysis, we realized we were not using enough wild-type DNA (likely due to a miscalculation of
the original DNA concentration). After correcting for this error, the QuikChange II site-directed
mutagenesis protocol was successful.
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4.2 Protein and DNA Gels
The purification process we used did successfully isolate our proteins of interest, but the
yields varied between proteins. The yield of the Sep5 protein was significantly lower than both
the wild-type (WT) P6 and P6 T42E mutant. This difference can be seen by comparing the
intensity of the protein sample bands for Sep5 (Figure 3.5) and both P6 gels (Figure 3.7). The
absorbance of the collected samples also reflected this difference, with P6 often reaching an
absorbance around 0.2 while Sep5 barely reached 0.02 at 280 nm. We made several attempts to
optimize the culture conditions and protein expression levels: varying culture temperatures and
timing of induction, sonication times, and the addition of surfactant to the lysis buffer. In an
effort to decrease protein loss in the column flow through (Figure 3.5), we increased the
incubation time of the beads with our lysate (to overnight). Although the Sep5 protein was no
longer in the column flow through (Figure 3.6), yields remained significantly lower than those of
wild-type P6. We did, however, make up for the low yields by repeating the
expression/purification process many times.
The purification and collection of both WT P6 and P6 T42E was much more successful.
The proteins were easy to isolate and eluted in high concentrations (Figure 3.7). The DNA gels
(Figure 3.8) were used mostly to confirm the presence of DNA before samples were sent off for
sequencing (after mutagenesis). Although all of the samples in Figure 3.8 were sent for
sequencing, the DNA for sample A1 matched the P6 T42E mutant perfectly and was used to
create glycerol stocks.
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4.3 Sep5 Analysis
Typically, an ideal protein sample for NMR experiments has a concentration between
0.5-1.0 mM (or higher). After many rounds of expression and purification, the Sep5 protein
samples were concentrated and exchanged into the appropriate buffer; we attempted an initial 1D
1

H NMR experiment on the sample. We initially ran the sample under the basic hydrogen

experiment parameters, but we saw no peaks indicating the presence of protein. In our second
trial we ran the same 1D 1H experiment but used an automated water suppression program called
“Watergate” to try and minimize interference from the water signal. However, as shown in
Figure 3.10, there were still no visible protein peaks. We also ran the NMR protein sample on a
gel (Figure 3.6) and were able to visualize a pronounced band at the correct molecular weight for
Sep5. Therefore, we knew Sep5 protein was present in the sample; we concluded that Sep5 was
denatured or aggregated and therefore undetectable in NMR spectroscopy. If a protein becomes
denatured or aggregated, its molecules will experience the same or very similar chemical
environment. This in turn disrupts the signal that would be seen in an NMR spectrum, especially
when looking at an HSQC spectrum of a protein. In a folded protein, each amino acid has a
specific chemical environment around it, which determines its chemical shift and location on an
HSQC spectrum. If the amino acids are seeing very similar or the same chemical environment,
the peaks would all be grouped in a single location and not widely distributed in the spectrum (as
would be the case for a disordered or unfolded protein).
Rather than continue to work out the problems of isolating the Sep5 protein, we decided
not to pursue the project further due to the initial NMR results and new information from other
experiments. Our original hypothesis was that the NTHi P5 protein was involved in flipping P6
to the surface of the cell. Joy Snyder, another member of the Michel lab, did a Pal (P6
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homologue) surface antibody binding test on an OmpA (P5 homologue) knockout using flow
cytometry (Figure 3.11). In flow cytometry, cells are passed through a laser beam one at a time; a
detector differentiates between whole cells and debris and between fluorescently labeled and
unlabeled cells. The samples were prepared using a basic antibody sandwich where the primary
antibody (Anti-Pal) bound to surface exposed protein in whole cells and a secondary antibody
conjugated to a fluorescent tag binds to the primary antibody (similar to Figure 1.2). Labeled
cells are shifted up away from unlabeled cells in the flow output plot. The results of the
experiment (Figure 3.11) show that Pal antibodies bind just as well and even slightly better to an
OmpA knockout cell (where OmpA in not expressed) compared to WT cells. We would predict
that if OmpA played an important role in flipping Pal to the cell surface of E. coli, we would not
see Pal on the surface of OmpA knockout cells. Therefore, the results of flow experiments
suggest that OmpA is not involved in the surface exposure of Pal. Due to this finding, and our
difficulty in obtaining folded Sep5, we decided to discontinue our work on OmpA/P5.

4.4 Mapping of the 4G4 Epitope
As previously mentioned, the 4G4 and 7F3 antibodies to NTHi P6 are known to compete
for similar binding sites. It was shown, in the Michel lab, that a single mutation at position 40
(D40N) greatly reduced 7F3 binding. This would indicate that the 4G4 epitope is in a nearby
region to residue 40. We decided to create a T42E (threonine to glutamic acid) mutant and test
for changes in 7F3 and 4G4 binding.
Although we confirmed the sequence results for the mutant, it was also important to
compare the structure of the P6 T42E mutant to wild-type P6 to ensure that the overall tertiary
structure was maintained. Recombinant wild-type and mutant proteins were isotopically labeled,
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using 15N-labelled ammonium chloride in M9 minimal media. To prepare the samples for NMR,
the protein was concentrated and exchanged into the final buffer, as described above. A BCA
assay was also performed to estimate the concentrations of the protein samples.
We once again started by collecting a 1D 1H NMR spectrum, and this time we did see
peaks around the 4.7 ppm water peak indicating folded protein (2-10 ppm, Figure 3.12). We also
collected a 1H-15N HSQC “fingerprint” spectrum for WT and mutant proteins, and overlapped
the spectra as shown in Figure 3.13. In a 2D HSQC spectrum, each 2D peak represents the amino
group of a specific amino acid in the protein sequence. The position (or frequencies) of these
peaks are very sensitive to the local and global structure of the surrounding environment within
the protein. By overlapping the spectra from the P6 T42E (pink/red) and wild type (blue/light
blue) we can clearly see that there is only a very small difference between the two proteins. The
differences in the spectra that are noticeable are most likely due to the mutation itself or small
local changes resulting from the mutation. We concluded that the tertiary structure of the T42E
mutant remained highly similar to that of wild-type P6.
In the ELISA, we tested two different concentrations of our proteins (T42E and WT) for
binding to P6 antibodies 4G4 and 7F3. The results for 4G4 binding did not vary significantly
between wild-type and the T42E mutant at either concentration, although the mutant did show a
slightly higher absorbance in the 50 ng per well assay (Figure 3.15). Interestingly, the 7F3
antibody did show a reasonably higher absorbance in the T42E mutant, indicating that the T42E
mutant has a higher binding affinity for 7F3, compared to WT P6 (Figure 3.14). This suggests
that although 7F3 binding is mediated by the aspartic acid residue at position 40, the amino acid
at position 42 may also play a role in binding. With two acidic residues in position 40 and 42 (in
the T42E mutant), 7F3 binding seems to be enhanced. We propose there is a basic patch of
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amino acids in the 7F3 binding site. In comparison, residue 42 does not seem to affect P6
binding to 4G4 at all. We propose that residue 42 is not part of the P6 epitope for 4G4 or that a T
to E mutation does not affect binding of 4G4 to P6. However, we are currently testing a different
mutant (T42R) to see if a more drastic change in that residue has any effect on antibody binding.
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5

Conclusions and Future Directions
In conclusion, the results of our flow cytometry experiments with the E. coli OmpA

knockout indicate that OmpA does not play a significant role in the surface exposure of Pal.
Based on these results, we believe that it is unlikely that P5 is involved in the surface exposure of
P6 in NTHi. Since our C-terminal fragment of P5 (Sep5) was not detected via NMR, and in light
of our flow results, we decided to discontinue work on our P5/OmpA hypothesis. However, the
recent structure of the C-terminal end of OmpA confirms our hypothesis that its structure is
highly similar to that of P6 [19].
Although the results of P6 T42E ELISA showed no significant change in P6 binding to
the mutant, there are other avenues that should be explored to identify the 4G4 epitope. Perhaps a
more significant mutation at position 42, such as from threonine to arginine (T42R) could
demonstrate whether residue 42 is essential for 4G4 binding. Also, further examination of the
structure of P6 may help reveal other possible surface exposed residues that could be part of the
4G4 epitope.
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